Wall Street Indexes Dip With Focus on Trump Policies, Economic Data
The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...
Hosted on MSN1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript
This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
kffhealthnews1d
STI Infections Are Slowing; Health Experts Call For Cautious Optimism
(Schnirring, 11/12) Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug application for its COVID-flu combination and standalone flu ...
Don’t wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines
Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Honolulu Star-Advertiser1d
Wall Street indexes dip with focus on economic data
Biotech firm Novavax dropped after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...
devdiscourse1d
Healthcare Headlines: Legal Battles, Financial Shifts, and Market Trends
This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
emjreviews.com2d
FDA Lifts Hold on COVID-Flu Combo Vaccine Trial
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
Becker's Hospital Review2d
FDA lifts clinical hold on combined COVID-19-influenza vaccine trials
Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that ...